Overview of SARS-CoV-2 genome-encoded proteins

C Bai, Q Zhong, GF Gao - Science China Life Sciences, 2022 - Springer
Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) has spread rapidly
throughout the world. SARS-CoV-2 is an enveloped, plus-stranded RNA virus with a single …

[HTML][HTML] Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies

M Yuan, H Liu, NC Wu, IA Wilson - Biochemical and biophysical research …, 2021 - Elsevier
Immediately from the outset of the COVID-19 pandemic, researchers from diverse
biomedical and biological disciplines have united to study the novel pandemic virus, SARS …

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

CO Barnes, CA Jette, ME Abernathy, KMA Dam… - Nature, 2020 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic presents an urgent health
crisis. Human neutralizing antibodies that target the host ACE2 receptor-binding domain …

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

A Schäfer, F Muecksch, JCC Lorenzi, SR Leist… - Journal of Experimental …, 2020 - rupress.org
SARS-CoV-2, the causative agent of COVID-19, has been responsible for over 42 million
infections and 1 million deaths since its emergence in December 2019. There are few …

Neutralizing antibody therapeutics for COVID-19

AC Hurt, AK Wheatley - Viruses, 2021 - mdpi.com
The emergence of SARS-CoV-2 and subsequent COVID-19 pandemic has resulted in a
significant global public health burden, leading to an urgent need for effective therapeutic …

[HTML][HTML] Neutralizing antibodies targeting SARS-CoV-2 spike protein

S Xiaojie, L Yu, Y Guang, Q Min - Stem cell research, 2021 - Elsevier
SARS-CoV-2 causing the worldwide pandemic has changed people's life in multiple aspects
dramatically since it's first identified in Wuhan, China at the end of 2019. While the numbers …

Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B. 1.617. 2 and implications for immune evasion

P Baral, N Bhattarai, ML Hossen, V Stebliankin… - Biochemical and …, 2021 - Elsevier
Following the initial surges of the Alpha (B. 1.1. 7) and the Beta (B. 1.351) variants, a more
infectious Delta variant (B. 1.617. 2) is now surging, further deepening the health crises …

Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2

CJ Bracken, SA Lim, P Solomon, NJ Rettko… - Nature chemical …, 2021 - nature.com
Neutralizing agents against SARS-CoV-2 are urgently needed for the treatment and
prophylaxis of COVID-19. Here, we present a strategy to rapidly identify and assemble …

Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies

R Yan, R Wang, B Ju, J Yu, Y Zhang, N Liu, J Wang… - Cell research, 2021 - nature.com
Neutralizing monoclonal antibodies (nAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) represent promising candidates for clinical intervention against …

Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19

YS Goh, JM Chavatte, AL Jieling, B Lee, PX Hor… - Cell Reports …, 2021 - cell.com
Early detection of infection is crucial to limit the spread of coronavirus disease 2019 (COVID-
19). Here we develop a flow cytometry-based assay to detect severe acute respiratory …